ZA201907715B - Vaccine comprising clostridium toxoids - Google Patents

Vaccine comprising clostridium toxoids

Info

Publication number
ZA201907715B
ZA201907715B ZA2019/07715A ZA201907715A ZA201907715B ZA 201907715 B ZA201907715 B ZA 201907715B ZA 2019/07715 A ZA2019/07715 A ZA 2019/07715A ZA 201907715 A ZA201907715 A ZA 201907715A ZA 201907715 B ZA201907715 B ZA 201907715B
Authority
ZA
South Africa
Prior art keywords
toxoids
clostridium
vaccine
clostridium toxoids
Prior art date
Application number
ZA2019/07715A
Other languages
English (en)
Inventor
Pérez Xavier Gibert
Arnau Marta Sitjà
Original Assignee
Hipra Scient S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hipra Scient S L U filed Critical Hipra Scient S L U
Publication of ZA201907715B publication Critical patent/ZA201907715B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2019/07715A 2017-06-09 2019-11-21 Vaccine comprising clostridium toxoids ZA201907715B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382358 2017-06-09
PCT/EP2018/065025 WO2018224595A1 (en) 2017-06-09 2018-06-07 Vaccine comprising clostridium toxoids

Publications (1)

Publication Number Publication Date
ZA201907715B true ZA201907715B (en) 2024-09-25

Family

ID=59078007

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07715A ZA201907715B (en) 2017-06-09 2019-11-21 Vaccine comprising clostridium toxoids

Country Status (8)

Country Link
US (1) US11154605B2 (https=)
EP (1) EP3634480A1 (https=)
JP (2) JP7349366B2 (https=)
BR (1) BR112019024412A2 (https=)
CA (1) CA3064357A1 (https=)
MX (1) MX388528B (https=)
WO (1) WO2018224595A1 (https=)
ZA (1) ZA201907715B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202509058A (zh) * 2023-08-24 2025-03-01 法商西華動物藥品股份有限公司 抗豬感染之多價疫苗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
KR20150133770A (ko) 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법

Also Published As

Publication number Publication date
JP2020522471A (ja) 2020-07-30
WO2018224595A1 (en) 2018-12-13
MX2019013779A (es) 2020-01-13
EP3634480A1 (en) 2020-04-15
JP2023113631A (ja) 2023-08-16
MX388528B (es) 2025-03-20
JP7349366B2 (ja) 2023-09-22
US20200188500A1 (en) 2020-06-18
US11154605B2 (en) 2021-10-26
CA3064357A1 (en) 2018-12-13
BR112019024412A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
GB201410971D0 (en) Vaccine
GB201518684D0 (en) Vaccine
PT3207053T (pt) Novos péptidos imunogénicos
SG11201912429RA (en) Personalized vaccine
ES2648672T5 (en) Improved hvt-vectored nd-ibd vaccine
SG11201707926WA (en) Streptococcal vaccine
ZA201606619B (en) New m.tuberculosis vaccines
ZA201607355B (en) Group a streptococcus vaccine
GB201522132D0 (en) Vaccine
GB201707367D0 (en) Vaccine compostions
GB201704417D0 (en) Improved li vaccine adjuvant
GB201616904D0 (en) Vaccine
GB201608821D0 (en) Vaccines
EP3222289A4 (en) Dna-peptide combination vaccine
ZA201907715B (en) Vaccine comprising clostridium toxoids
GB201811382D0 (en) Vaccine
GB201703529D0 (en) Vaccine composition
SI3188755T1 (sl) Cepivo
GB201419061D0 (en) Conjugated Vaccine
GB201603029D0 (en) Vaccine
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
GB201704892D0 (en) Improved vaccines
GB201712904D0 (en) Vaccine
GB201707785D0 (en) Vaccination